Natural Remedies (Bangalore, India) has announced the results of a randomized, double-blind clinical study conducted on its ingredient Turmacin, an extract of turmeric. In the study, which is expected to be published in November, 90 healthy volunteers with joint discomfort or pain of at least greater than 40 mm on VAS (Visual Analogue Scale) during 10 minutes of exercise on stepmill equipment, were randomized to receive either placebo, 500 mg of Turmacin, or 1,000 mg of Turmacin daily for 12 weeks.
Post-stepmill exercise pain scores and the time of the initial pain/discomfort onset were recorded at baseline, day 5, 7, 28, 56, and 84. Researchers also recorded range of motion and peak torque for muscle contraction at the joint at the end of 12 weeks using digital goniometry and isokinetic dynamometry, respectively. Results showed that, compared to placebo, Turmacin significantly decreased the final pain scores from day 5, with the biggest decrease of 1.7 units on the VAS scale from baseline seen on days 56 and 84.
“Overall, the study suggests that Turmacin showed promising results for alleviating joint discomfort that arises during exertion or exercise,” said Suresh Lakshmikanthan, global head of human health business for Natural Remedies, in a press release. “Sports recovery product applications with Turmacin now range from capsules and tablets, to shots, chews, gummies, protein powders, bars, and beverages.”
This is the second clinical trial substantiating Turmacin for joint and cartilage support, adds Lakshmikanthan. The ingredient is also GRAS and water soluble, making it ideal of functional beverage applications. Uniquely, Turmacin is untouched by solvents, and does not contain curcuminoids, instead it is standardized to contain bioactive polysaccharides that are trademarked Turmerosaccharides. AIDP Inc. is the exclusive North American distributor of Turmacin.